Day: March 20, 2025

Reports record-high revenues since inception MONTREAL, March 20, 2025 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”), a pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its fourth quarter and year ended December 31, 2024. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified. 2024 Highlights Financial resultsRevenues were $371,304, an increase of $43,105 or 13% over the prior year. The increase was driven by the growth of our key promoted products, the impact of hyperinflation in Argentina, partly offset by declines of our mature products and the depreciation of select LATAM currencies. Gross margin was $174,405 or 47% of revenues compared to $152,652 or 47%...

Received European Commission approval for GOHIBIC® (vilobelimab) for the treatment of SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) Achieved 30-patient recruitment milestone in Phase 3 vilobelimab trial in pyoderma gangrenosum (PG) to enable an expected interim analysis for trial size adaptation or futility by the end of May 2025 Dosed first patient in Phase 2a trial for oral C5aR inhibitor, INF904, with topline data in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected in summer 2025 Multiple data presentations at AAD 2025 highlighting the potential of vilobelimab in reducing systemic inflammation Cash, cash equivalents and marketable securities of €55.2 million as of December 31, 2024 Additional €28.7 million ($30.0 million) in gross proceeds subsequently raised by an underwritten public offering...

Achieved Q4 2024 PEMGARDA™ (pemivibart) net product revenue of $13.8 million, representing 48% growth over Q3 2024 net product revenue of $9.3 million; full-year 2024 net product revenue totaled $25.4 million 2024 year-end cash and cash equivalents of $69.3 million Continues to target near-term (by end of 1H 2025) profitability with existing cash and cash equivalents, anticipated growth of net product revenue, and continued reduction of manufacturing expenses Company announced in vitro neutralization data show continued, consistent neutralizing activity of PEMGARDA against LP.8.1, KP.3.1.1, and XEC, comprising the majority of SARS-CoV-2 variants currently circulating in the U.S, reinforcing the durability of PEMGARDA’s neutralizing activity shown amid viral evolution Company announced positive Phase 1 clinical data for next-generation...

A Pivotal Year, Marking Accomplishment of Strategic Shift to Data Collection, Hits Milestones Toward Becoming a Driving Force in the AI Revolution 2024 revenue increased to $31.8 million, of which $7.4 million was in the fourth quarter;2024 net profit rose to $5.8 million and adjusted EBITDA reached $9.4 million; Cash and liquid investments balance at year-end amounted to $25 million TEL AVIV, Israel, March 20, 2025 (GLOBE NEWSWIRE) — Alarum Technologies Ltd. (Nasdaq, TASE: ALAR) (“Alarum” or the “Company”), a global provider of web data collection solutions, today announced financial results for the fourth quarter and full year ended December 31, 2024. Shachar Daniel, Chief Executive Officer of Alarum, said: “2024 was a landmark year for Alarum, as we successfully executed our strategic vision, to focus on data collection. This...

Duke Robotics’ successful transition from development to commercialization, highlighted by a service agreement with the Israel Electric Corporation, strategic European expansion with the establishment of Greek subsidiary, as the company eyes fast growing civilian utility maintenance market with its innovative drone technologies FORT LAUDERDALE, FL, March 20, 2025 (GLOBE NEWSWIRE) — Duke Robotics Corp. (OTCQB: DUKR) (“Duke Robotics” or the “Company”), a leader in advanced robotics technology and autonomous drone solutions, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a corporate update. Yossef Balucka, Chief Executive Officer of Duke Robotics, commented: “2024 was a transformative year for Duke Robotics, marked by our successful transition...

Positive Results with Zervimesine (CT1812) in Phase 2 SHIMMER Dementia with Lewy Bodies (DLB) Phase 2 SHINE Data Show Dramatic Slowing of Cognitive Decline with Zervimesine in a Key Pre-specified Alzheimer’s Disease Subgroup 2025 Objective: Advance Zervimesine into Late-stage Trials for DLB and Alzheimer’s Disease Management will Review Results at 8:00 a.m. ET on Live Webcast and Conference Call PURCHASE, N.Y., March 20, 2025 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update. Data readouts in 2024 from the Company’s Phase 2 studies in mild-to-moderate Alzheimer’s disease...

Phase 1 MAD dosing completed for SION-451 and final MAD cohort of SION-719 planned; Interim data in healthy volunteers show potential to provide clinically meaningful benefit to CF patients. Topline data anticipated in first half of 2025 On track to initiate NBD1 Phase 2a proof-of-concept trial in combination with SOC in CF patients and combination MAD trials of an NBD1 stabilizer with a complementary modulator in healthy volunteers in the second half of 2025, with topline data for both anticipated in mid-2026 Completed upsized IPO with gross proceeds of approximately $219 million, extending runway into 2028 WALTHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) — Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by...

Full-Year Sales of $467.0 million, Net Income of $3.1 million, $0.05 EPS, Adjusted EBITDA of $19.9 million CANTON, Mass., March 20, 2025 (GLOBE NEWSWIRE) — Destination XL Group, Inc. (NASDAQ: DXLG), the largest integrated commerce specialty retailer of Big + Tall men’s clothing and shoes, today reported financial results for the fourth quarter and fiscal year 2024. Fourth Quarter HighlightsTotal sales for the 13-week fourth quarter were $119.2 million, down 13.1% from $137.1 million for the 14-week fourth quarter of fiscal 2023. Comparable sales for the fourth quarter decreased 8.7% as compared to the fourth quarter of fiscal 2023. Net loss for the fourth quarter was $(1.3) million, or $(0.02) per diluted share, as compared to net income of $5.2 million, or $0.08 per diluted share, for the fourth quarter of fiscal 2023. Adjusted...

$7.3 million in total neffy® (epinephrine nasal spray) U.S. net product revenue in 2024 since launch in late September 2024 neffy 1 mg approved by U.S. FDA for children aged four and older and weighing 15 kilograms to < 30 kilograms (33 lbs. to < 66 lbs.), expanding the reach of neffy to approximately 2 million younger, school-aged children at risk of a severe allergic reaction $314.0 million in cash, cash equivalents, and short-term investments at year-end 2024, supporting an increased investment in commercialization in 2025 while maintaining an operating runway of at least three years Company to host conference call today, March 20, 2025 at 5:30 a.m. PT / 8:30 a.m. ET SAN DIEGO, March 20, 2025 (GLOBE NEWSWIRE) —  ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and...